Volume 4.04 | Feb 2

Mammary Cell News 4.04 February 2, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Researchers Discover a Rotational Motion of Cells that Plays a Critical Role in Their Normal Development
In a study that holds major implications for breast cancer research as well as basic cell biology, scientists have discovered a rotational motion that plays a critical role in the ability of breast cells to form the spherical structures in the mammary gland known as acini. [Press release from the U.S. Department of Energy’s Lawrence Berkeley National Laboratory discussing online prepublication in Proceedings of the National Academy of Sciences USA] Press Release | Abstract

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
PUBLICATIONS (Ranked by Impact Factor of the Journal)


Leptin Mediates Tumor-Stromal Interactions that Promote the Invasive Growth of Breast Cancer Cells
In this study, researchers identify a role for the obesity cytokine leptin, which has been implicated previously in breast cancer development, as a determinant for the tumor-promoting activity of cancer-associated fibroblasts in both wild-type and K303R mutant ERα-expressing breast cancer cells. [Cancer Res] Abstract

The PKCθ Pathway Participates in the Aberrant Accumulation of Fra-1 Protein in Invasive ER-Negative Breast Cancer Cells
Here, researchers show that the concentration of Fra-1 is high in invasive estrogen receptor (ER)-negative breast cancer cell lines, regardless of their Ras pathway status. [Oncogene] Abstract

The ShcA SH2 Domain Engages a 14-3-3/Phosphatidylinositol 3 Kinase Signaling Complex and Promotes Breast Cancer Cell Survival
Using transplantation approaches, researchers demonstrate that Src homology 2 domain (SH2)-dependent ShcA signaling within the mammary epithelial compartment is essential for breast tumor outgrowth, survival and the development of lung metastases. [Oncogene] Abstract

Estrogenic Regulation of S6K1 Expression Creates a Positive Regulatory Loop in Control of Breast Cancer Cell Proliferation
In this report, researchers demonstrate that estrogen activates expression of S6 kinase 1 (S6K1) via estrogen receptor (ER)α in ER-positive breast cancer cells. [Oncogene] Abstract

Phospho-Ibuprofen (MDC-917) Suppresses Breast Cancer Growth: An Effect Controlled by the Thioredoxin System
Researchers have recently synthesized MDC-917, a safer derivative of ibuprofen, which has shown anticancer activity. Here, researchers investigated its efficacy and mechanism of action in the treatment of breast cancer in preclinical models. [Breast Cancer Res] Abstract

Inactivation of GPR30 Reduces Growth of Triple-Negative Breast Cancer Cells: Possible Application in Targeted Therapy
Triple-negative breast tumors frequently express membrane bound estrogen receptor G-protein coupled receptor (GPR30). As proof of principle, researchers analyzed the consequences of a knock-down of GPR30 expression on the growth regulation of triple-negative breast cancer cell lines. [Breast Cancer Res Treat] Abstract

Adenovirus-Mediated Aurora A Short Hairpin RNA Driven by Stathmin Promoter Suppressed Tumor Growth and Enhanced Paclitaxel Chemotherapy Sensitivity in Human Breast Carcinoma Cells
In this study, researchers developed a novel tumor-specific RNA interference adenovirus system targeting Aurora A by using stathmin promoter and investigated the effects of it on the proliferation, apoptosis and chemotherapy sensitivity in human breast carcinoma cells both in vitro and in vivo. [Cancer Gene Ther] Abstract

Loss of miR-133a Expression Associated with Poor Survival of Breast Cancer and Restoration of miR-133a Expression Inhibited Breast Cancer Cell Growth and Invasion
Cell viability, migration, and invasion assays were used to determine the role of miR-133a in regulation of breast cancer cell growth, migration, and invasion, respectively. [BMC Cancer] Abstract


IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors
The purpose of this study was to improve the significance of insulin-like growth factor binding protein 5 (IGFBP-5) as a prognostic and potentially predictive marker in breast cancer patients. [Clin Cancer Res] Abstract

An Open-Label, Phase II Trial of RPI.4610 (Angiozyme) in the Treatment of Metastatic Breast Cancer
This phase II, multicenter, single-arm study was designed to assess the objective response rate of RPI.4610 in patients with metastatic breast cancer (MBC) who had experienced disease progression with at least one course of chemotherapy for MBC. [Cancer] Abstract

Clinical Significance of CD151 Overexpression in Subtypes of Invasive Breast Cancer
In this study, CD151 overexpression was found to be significantly associated with larger tumor size, higher nodal stage, advanced stage, absence of oestrogen receptor and progesterone receptor, and human epidermal growth factor receptor 2 overexpression. [Br J Cancer] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response


World-Class Scientists Chosen for HHMI’s First International Early Career Award
Top biomedical scientists from 12 countries will receive an important boost at a critical time in their careers from the Howard Hughes Medical Institute’s (HHMI’s) inaugural International Early Career Scientist awards. [Howard Hughes Medical Institute] Press Release

Pertuzumab Plus Trastuzumab and Docetaxel Will Become Decision Resources’ Proprietary Clinical Gold-Standard Treatment for Metastatic First-Line HER2-Positive Breast Cancer in 2015
Decision Resources finds that, based on clinical data and the opinions of interviewed thought leaders, Roche/Genentech/Chugai’s pertuzumab plus trastuzumab and docetaxel will become Decision Resources’ proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015, following its launch for the indication in 2012 in the U.S. and Europe and in 2013 in Japan. [Decision Resources, LLC.] Press Release

Signal Genetics Announces Acquisition of ChipDX LLC and Expansion of Molecular Diagnostics Assets in Oncology
Signal Genetics (Signal) announced an agreement with New York based ChipDX LLC (ChipDX), under which Signal will acquire all of the assets of ChipDX, including patents for prognostic tests in lung, breast, and colon cancers. [Business Wire] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW European Institute of Oncology – 14th Milan Breast Cancer Conference
June 20-22, 2012
Milan, Italy

Visit our events page to see a complete list of events in the mammary cell community.

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies, Inc.)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Postdoctoral Positions (Cancer Science Institute of Singapore)

Postdoctoral Fellow and Technician Positions (North Carolina Central University)

Postdoctoral Research Scientist (The Beatson Institute for Cancer Research) 

Associate Professor – Breast Pathology (Tianjin Medical University Cancer Institute and Hospital) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada